Thai FDA takes tough action against the advertisements on health products which are illegal. The illegal advertisers may have a jail term, fine, website blockade or even cancellation of licenses of broadcasting. “A website falsely advertised that migraine can be treated by honey milk while another claimed virility boosts by usage of its product. The two websites have been cracked down and offenders will be fined and jailed” said Dr Boonchai Somboonsuk, FDA secretary general. READ ALSO: Medical Device Registration In Thailand
The maximum fine under the FDA law is Bt 5000 but the FDA through other relevant laws is making the offenders get more punishment. National Broadcasting and Telecommunications Commission (NBTC) will suspend broadcaster’s licenses who are engaged in offending. “Starting from three days suspension, the offenders may get a longer suspension who is frequent and may be revoked if found non-stoping” said NBTC member Supinya Klangnarong. The television stations might get a Bt5million fine if found offensive. 483 websites are about to be blocked for illegal advertisement posting by the Information and Communications Technology Ministry. READ ALSO: Other South East Asian Markets Regulatory Overview.
Other News
CDSCO Issues Guidelines on Medical Device License Retention
New Delhi, May 15, 2024 — The Central Drugs Standard Control Organization (CDSCO) has released a circular (F. No. MED-15/35/2024-eOffice) on the retention of medical device licenses and certificates under the Medical Devices Rules, 2017. […]
Read More
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
